Chen Y, et al. - The efficacy and safety of the paclitaxel plus fluorouracil regimen vs the cisplatin plus fluorouracil regimen in definitive concurrent chemoradiotherapy (dCRT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC) were assessed in this trial. Researchers recruited 436 patients with ESCC in six centers at a 1:1 ratio. Outcomes revealed no significant prolongation of overall survival (OS) with the paclitaxel plus fluorouracil regimen when compared with the standard cisplatin plus fluorouracil regimen in dCRT in these patients.